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ABSTRACT. A cohort of 93 short-statured chil-
dren and adolescents undergoing GH treatment
were evaluated with respect to behavior, emo-
tions, and attitudes. The sample consisted of pa-
tients suffering from either idiopathic GH de-
ficiency or neurosecretory dysfunction (no.=47),
Turner syndrome (no.=20), organic GH deficien-
cy due to brain tumors (no.=10), or other etiolo-
gies (no.=16). The Child Behavior Checklist (CB-
CL) together with a brief Evaluation of Treatment
Questionnaire (ETQ) were filled out by the pa-
tient’s parents. These evaluations were per-
formed at onset and after 12 and 24 months of
GH treatment, respectively. There was a highly
significant but clinically small decline of behav-
ioral abnormalities over time and parents saw
major benefits of GH treatment in the total
group of patients. The behavioral changes over
time were independent of diagnostic category,
gender, height velocity, puberty and age. 
(J. Endocrinol. Invest. 25: 351-356, 2002)
©2002, Editrice Kurtis
INTRODUCTION
Various studies indicate that children with short
stature are at increased risk for psychological mal-
adjustment due to low self-esteem, stigmatiza-
tion, and inadequate coping (1-3). These studies
found distinct personality features, lower self-es-
teem, increased rates of behavior problems, and
lower social competence in short-statured chil-
dren (4-9). 
In contrast, there is another small series of studies
that found on average normal psychological func-
tioning in their subjects (10-16). The obvious dif-
ferences in results may be due to different patient
selection, the variety of psychological instruments
that were used, and the various informants, in-
cluding parents, teachers, and the children them-
selves that were used in the various studies. In ad-
dition, referral bias may have contributed to the
assumption that short stature implies a psycho-
logical handicap (14-15). In fact, a recent study has
shown that non-referred short children in the pop-
ulation in contrast to short children referred for
evaluation and treatment do not show behavioral
abnormalities (17).
During the last 3 decades, short statured children
have been treated with GH, but very limited psy-
chological evaluation has been done on the effects
of this kind of intervention. The first trials indicated
that there are no behavioral effects of GH replace-
ment per se. Clopper (18) concluded in his review
that, as a group, children undergoing GH treat-
ment, while not grossly maladjusted, are prone to
experience problems with academic achievement
and social adjustment. At that time, there was also
conflicting evidence that GH treatment is associat-
ed with behavioral improvement. 
During the last 10-12 yr, recombinant human GH
treatment with daily sc injections has entirely re-
placed pituitary GH treatment. A few studies have
been launched in order to evaluate the behavioral
effects of this more recent treatment approach.
However, beyond the study outlines, very limited
findings have been reported so far (1, 10, 19-21).
Currently, there is conflicting evidence concerning
whether or not GH treatment has beneficial be-
havioral effects on short statured children (22, 23).
Thus, the present study was undertaken in order to
shed some light on the issue of a definite behav-
ioral effect of GH treatment.
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MATERIAL AND METHODS
Subjects
Short statured patients were recruited by pediatric endocrinol-
ogists from 68 children hospitals in Germany. Due to the inclu-
sion criteria of the psychological study (chronological age of at
least 4 yr; allowance for a time discrepancy of somatic and psy-
chological assessment of ±3 months at T2 and T3), only 93 (39.2
%) of a total of 237 patients could be studied longitudinally.
Based on clinical and laboratory assessments patients were
grouped by the doctors into the following diagnostic categories:
short stature due to: 1) idiopathic growth hormone deficiency
or neurosecretory dysfunction (IGHD; no.=47), 2) Turner syn-
drome (TS; no.=20), 3) organic growth hormone deficiency
(OGHD) due to brain tumors (no.=10), 4) other etiologies, in-
cluding idiopathic short stature, chronic inflammatory disease, or
chronic renal insufficiency (other etiologies (OE); no.=16). Thus,
a total of 93 patients were evaluated for treatment with human
GH (Somatropin; daily sc injections), and their auxological and
laboratory data were documented within the Kabi Pharmacia
International Growth Study (KIGS). A good response to GH
treatment was defined by a constant height velocity of >+1 stan-
dard deviation score (SDS)  at both 12 and 24 months. Start of
puberty was defined by Tanner stage B2 for girls and testicular
sizes 4 ml for boys.
Auxological and socio-demographic data of the subjects are shown
in Table 1. The four groups did not differ significantly with regard
to chronological age and social class distribution, whereas height
SDS’s [German references values (24)] were significantly lower
(p<0,01) in patients with IGHD, TS, and OE than in patients with
OGHD at the start of GH treatment. The mean GH dose was sig-
nificantly higher (p<0.01) In groups 2 (TS) and 4 (OE) than in groups
1 (IGHD) and 3 (OGHD). Mean target height SDS of group 3 was
significantly higher in comparison with the other groups. GH treat-
ment induced a significant increase of height velocity and height
velocity SDS in all groups after 1 and 2 yr.
Furthermore, a comparison of the auxological and GH treatment
data (6 variables) of the 93 participants and the 144 non-partic-
ipants did not reveal any statistically significant difference so
that there was no selection bias of patients. A separate table
may be requested from the Authors.
Procedure 
GH stimulation tests and GH measurements were performed in
the labs of the German children hospitals that are participating in
the multicenter KIGS. Serum GH levels were measured locally by
different methods. GH deficiency (GHD) was defined as a maxi-
mum GH level <10 ng/ml in 2 stimulation tests. Neurosecretory
dysfunction (NSD) was defined as mean GH levels <3 ng/ml after
an overnight spontaneous secretion profile (at least 30 samples).
GH dose was not tailored by measuring IGF-I levels. The latter are
not monitored in the KIGS. A good response to GH treatment was
defined by a constant height velocity of >+1 SDS at both 12 and
24 months. Start of puberty was defined by Tanner stage B2 for
girls and testicular sizes 4 ml for boys.
Behavioral assessment took place at baseline before treatment (t1),
and after 12 (9-15) months (t2) and 24 (21-27) months (t3) on GH
therapy. At these times, German speaking parents filled out 2 que-
stionnaires in terms of parallel forms. First, the German version of
the Child Behavior Checklist (CBCL) was used (25). The items of the
behavior problem section of the CBCL are grouped into 9 corre-
sponding cross-informant syndromes labeled Withdrawn, Somatic
Complaints, Anxious/Depressed, Social Problems, Thought Pro-
blems, Attention Problems, Delinquent Behavior, and Aggressive
Behavior. From these syndromes 2 broad-band second-order scales
are derived. These scales are called Internalizing Behavior and Exter-
nalizing Behavior and reflect the distinction between fearful, inhib-
ited, and overly controlled behavior on the one hand and aggres-
sive, antisocial, and under controlled behavior on the other hand.
Furthermore, a total score is computed. Scores are expressed on a
T-scale (mean=50, SD=10). In addition to the CBCL parents were
asked to respond to a total of 10 questions in order to evaluate the
attitude towards treatment. Because of the small number of items,
there was no intention of forming a scale but rather the items were
analyzed descriptively. 
Table 1 - Auxological (medium values) and sociodemographic data at start, first year and second year of GH-treatment.
IGHD (no.=47; 35 M, 12 F) TS (no.=20; 20 F) OGHD (no.=10; 7 M, 3 F) OE (no.=16; 8 M, 8 F)
Start 1 yr 2 yr Start 1 yr 2 yr Start 1 yr 2 yr Start 1 yr 2 yr
CA 9.3 10.3 11.3 9.2 10.2 11.2 11.6 12.4 13.4 8.8 9.8 10.8
Height SDS (CA) -3.3 -2.4 -2.0 -3.6 -3,1 -2,9 -2.1 -1.6 -1.3 -4.0 -3.5 -3.0
Height velocity (cm/yr) 4.4 8.8 7.8 4.2 7.6 6.6 1.8 8.1 7.9 4.4 8.3 7.6
Height velocity standard -1.6 +2.4 +1.8 -2,3 +1,8 +1,2 -3.0 +2.4 +2.5 -1.5 +2.6 +1.2
deviation score (SDS) (CA)
GH dose (IU/kg/week) 0.50 0.54 0.57 0.87 0.91 0.85 0.44 0.47 0.53 0.66 0.77 0.72
Pubertal stages
Tanner 1 40 34 28 20 17 14 9 8 8 15 15 14
Tanner G2/B2 or more 7 13 19 0 3 6 1 2 2 1 1 2
Target Height SDS -1.31 -1.17 -0.57 -1.18
SES (no)
Lower class 21 11 6 8
Middle class 18 9 3 8
Missing data 8 - 1 -
CA: chronological age; IGHD: idiopathic GH deficiency; OE: other etiologies; OGHD: organic GH deficiency; SDS: standard deviation score; SES: so-
cioeconomics status; TS: Turner syndrome.
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Statistical analyses
Data were analyzed by use of multivariate analyses of variance
(MANOVA) and multiple regression analyses.
RESULTS
Firstly, the CBCL scale scores were analyzed controll-
ing for the 3 times of assessment (repeated mea-
surements), diagnostic category, and gender. The
time factor indicating a significant decline of scores
was significant for the following CBCL scales
(Fig. 1): social withdrawal (WILKS LAMBDA=0.91,
F=4.22, p=0.02), somatic complaints (WILKS LAMB-
DA=0.922, F=3.59, p=0.03), anxious/depressed
(WILKS LAMBDA=0.869, F=6.38, p=0.003), and delin-
quent behavior (WILKS LAMBDA=0.928, F=3.32,
p=0.04). As a consequence (Fig. 2) both secondary
scales for measuring internalizing behaviors (WILKS
LAMBDA=0.871, F=6.31, p=0.003) and externalizing
behaviors (WILKS LAMBDA=0.927, F=3.34, p=0.04),
and the total score (WILKS LAMBDA=0.905, F=4.46,
p=0.01) showed a significant decline over time. There
were no further significant effects on any scales scores,
neither by diagnostic category nor by gender or any
interaction of factors. 
In order to better understand the potential deter-
minants of behavioral change, 2 alternative hypo-
theses were tested. The first asked whether or not
effective GH treatment itself resulted in behavioral
changes, whereas the second hypothesis asked for
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Fig. 1 - Mean Child Behavior Checklist
(CBCL) primary scale scores at baseline
(t1), after 12 months (t2), and after 24
months (t3) in the total group of patients
(no.=93).
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developmental changes as reflected by increasing
age and pubertal development. 
When testing the first hypothesis the total group of
patients was split into those patients who had grown
successfully during the entire treatment period and
those in whom there was a good growth response
only in one of the two observation periods (t1 to t2, or
t2 to t3). For the behavioral scores of the CBCL, dif-
ferences between t1 and t3 measurements were cal-
culated. These difference scores were then compared
between the groups with different height velocities
during GH and either present or absent onset of pu-
berty. Multivariate analyses across the 8 CBCL scales
indicated that there was only a trend for a growth ef-
fect (WILKS LAMBDA=0.852, F=1.74, p=0.10) but no
effect for onset of puberty (WILKS LAMBDA=0.890,
F=1.30, p=NS). For the more aggregated scores of
Internalizing and Externalizing Behaviors and the to-
tal scores, none of the various analyses for the CBCL
scores resulted in any significant effect for either
growth or onset of puberty. Subsample sizes were
too small to analyze any differential effect for diag-
nostic category in these analyses. 
The alternative hypothesis that the observed changes
were due to developmental changes was tested by
analyzing age effects. For the CBCL data, age at t2
was categorized into 3 groups (<6, 6-13, >13 yr).
There were no significant age effects (WILKS LAMB-
DA=0.818, F=1.10, p=NS) across the 8 primary scales. 
Furthermore, the parents’ satisfaction with the treat-
ment was evaluated both at t2 and t3. Findings are
shown in Table 2. In general, the parents provided
a favorable evaluation of treatment and showed lit-
tle criticism. The responses at t2 did not differ
markedly from t3 responses. 
Finally, we tried to predict the change in behavior,
i.e., in the CBCL total score by the following vari-
ables: age, sex, socioeconomic status, and growth.
The dependent variable was the difference be-
tween the two CBCL total scores that were measured
at t1 and t3. Multiple regression analyses indicated
that none of these variables was significantly relat-
ed to the difference in CBCL total scores.
DISCUSSION
This pilot study clearly has some limitations, namely
the relatively low participation rate of the original sam-
ple and the reliance on a single source of information,
i.e., the parent. However, the present study does not
suffer from a selection bias of patients and is based
on a sufficiently large sample of short statured chil-
dren and adolescents who underwent GH treatment.
Repeated behavioral evaluations showed that the
overall effect on growth was associated with a decline
of questionnaire scores for behavioral and emotional
abnormalities according to the parents’ evaluation.
These changes are significant but small in magnitude
because all mean profiles are within the normal range. 
However, the question as to the causal relation bet-
ween behavioral changes and growth is not easy to
answer. First, it has to be admitted that conclusions
are jeopardized due to the lack of an untreated con-
trol group. Thus, the possibility cannot be entirely ru-
led out that the observed changes reflect the statisti-
cal phenomenon of regression toward the mean of
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Fig. 2 - Mean Child Behavior Checklist (CBCL) secondary scale
scores at baseline (t1), after 12 months (t2), and after 24 months
(t3) in the total group of patients (no.=93).
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the distribution over time. Whereas it would have been
unethical to withhold treatment from a treatable con-
trol group, we were not in a position to repeatedly
evaluate a control group of short statured children
without an indication for GH treatment. Even a re-
ferred group of children with normal or idiopathic short
stature would have been unsuitable because of a po-
tential selection bias favoring psychosocial liability. 
Alternatively, we performed various analyses as to the
association of growth and behavioral changes. Clear-
ly, there was no significant relation between these 2
parameters. Neither there was significant association
between onset of puberty and behavioral changes.
The alternative test for age as a significant predictor
of behavioral changes also did not result in a viable
explanation. Thus, there is little room for the as-
sumption that our patients became less maladjusted
with increasing age, reflecting a general pattern of
psychosocial maturation. Although there are indica-
tions from this study that GH treatment is well toler-
ated and that parents perceive a strong association
between the decline of distress and the decline of
behavior abnormalities, the link between growth and
behavior was not as evident as one might expect.
Hypothetically, some mediating psychological vari-
able might create a causal relation between growth
and decline of behavioral and emotional abnormali-
ties. Variables of this kind might include improved
coping skills or self-esteem that have been found to
be relevant in many short statured children. Besides a
relatively simple assessment in one study (20), these
variables have so far not been studied in patients un-
dergoing GH treatment and certainly deserve more
attention in future studies. Furthermore, as Stabler et
al. (21) have suggested, the effects may be related to
the putative social value associated with increased
height, the changing expectations of the parents, and
perhaps even indirect effects of GH treatment on the
brain due to neuroendocrine mechanisms. However,
the latter would pertain mainly to the modulation of
mood, affects, and attention via hypothalamic-pituita-
ry mechanisms. Whereas this is a potential explana-
tion for the decline of mainly internalizing behaviors,
as found in the Stabler et al. study (21), this would be
a less viable explanation for the decline of Externaliz-
ing Behaviors that were also seen in the present study. 
Furthermore, here was no significant effect on be-
havioral change by diagnostic category. These find-
ings match our previous results in the larger sample
of 311 children and adolescents with the same di-
agnostic categories (9). From these previous stud-
ies we concluded that probably short stature per
se, rather than a specific diagnosis has an impact
on behavioral adaptation. Thus, future studies with
different diagnoses may wish to find out whether
or not there is a specific effect of diagnosis on be-
havioral change in association with GH treatments. 
So far, there is little room for comparison with oth-
er studies. Attempts to evaluate the behavioral ef-
fects of GH treatment have been scarce, and the
sample compositions are different as regards the
diagnostic entities that were included. Our findings
of small, but statistically significant positive behav-
ioral changes in association with GH treatment are
somewhere between the observations of a recent
collaborative study by Stabler et al. (21), who also
used the CBCL for the evaluation of GH treatment
over a 3-yr period, and the more reserved conclu-
sion of a recent study by Downie et al. (10) that, to
date, no psychological benefits of GH treatment
have been shown. Long-term outcome studies must
show whether any substantial behavioral effects are
sustained and prevent the quality of life of short
statured adults from being impaired. 
Table 2 - Evaluation of treatment (percentages) by parents in the total group of patients (no.=93). 
t2 t3
12 months 24 months
1.  Treatment did not only help physically 84 76
2.  Treatment is being experienced as distressing 19 22
3.  Resistance towards the injections 4 19
4.  Significant developmental progress since onset of treatment 84 70
5.  Wish for discontinuation of treatment 2 10
6.  Problems of coping with growth 4 11
7.  Continuous encouragement needed in order to continue with treatment 14 17
8.  Desire for remaining short 2 5
9.  Acceptance of inconvenience of treatment because of desire to grow 97 81
10.  Unproblematic treatment 82 65
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